PatentsGlobal
Erasca Inc. Hit with Securities Class Action Following Patient Death and Patent Infringement Claims, $2.8 Billion Market Cap Plummets
Erasca, Inc. (NASDAQ: ERAS), a precision oncology company developing the pan-RAS molecular glue ERAS-0015, faces a securities class action after its stock plunged 48% following disclosures of a patient death and patent infringement allegations by Revolution Medicines. The lawsuit targets investors who acquired Erasca…
Thursday, June 25, 2026